Loading clinical trials...
Loading clinical trials...
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Revolution Medicines, Inc.
NCT07542041 · Pancreatic Cancer, Pancreatic Neoplasms, and more
NCT07536113 · Metastatic Colorectal Cancer (CRC)
NCT06476808 · High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), and more
NCT07228832 · Metastatic Colorectal Cancer (CRC)
NCT07361497 · Non-small Cell Lung Cancer (NSCLC)
University of California, Davis Comprehensive Cancer Center
Sacramento, California
Smilow Cancer Hospital (Yale University)
New Haven, Connecticut
Florida Cancer Specialists
Sarasota, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions